Summarized by Masters of Longevity from MedTech Dive.
Galvanize closed a $130 million Series D to commercialize Aliya PEF.

Key Takeaways
- Series D funding is headed to Aliya commercialization efforts.
- PEF is reported to kill cells while preserving tissue matrix.
- RheOx development for chronic bronchitis is advancing in parallel.



